期刊文献+

基于多核学习的弥漫大B细胞淋巴瘤早期复发的精准预测

Precise Prediction of Early Recurrence of Diffuse Large B-cell Lymphoma based on Multi-Kernel Learning
下载PDF
导出
摘要 目的对山西省某三甲医院2011-2017年间血液科新诊断的弥漫大B细胞淋巴瘤患者(diffuse large B-cell lymphoma,DLBCL)是否实现两年无事件生存,即DLBLC患者早期复发的预测。方法根据无事件生存期,将患者分成早期复发和非早期复发,并以此为标签构建分类模型。首先对数据进行了归一化处理,然后用LASSO进行了特征选择,因数据类别不平衡,分别采用了SMOTE(synthetic minority over-sampling technique)、Borderline-1 SMOTE、Borderline-2 SMOTE与ADASYN(adaptive synthetic sampling)四种方法平衡数据,之后构建了基于支持向量机的多核模型作为最终的分类器,并与AdaBoost、随机森林和以高斯核、多项式核为内核的单核支持向量机进行比较,最终实现对新诊断病例早期复发的预测。结果在本文所有模型中,采用LASSO加Borderline-1 SMOTE的多核模型(accuracy=0.87,precision=0.87,recall=0.87,f1=0.87,AUC=0.87)取得了最优的分类性能。采用SMOTE的随机森林模型(accuracy=0.84,precision=0.85,recall=0.87,f1=0.79,AUC=0.83)、Borderline-2 SMOTE的随机森林(accuracy=0.84,precision=0.85,recall=0.87,f1=0.79,AUC=0.83)两种集成模型的分类性能也较好,但都低于多核支持向量机模型。两种单核支持向量机性能较差。结论本文构建的所有模型中,经过LASSO和Borderline-1 SMOTE重采样的多核支持向量机性能最优,可为DLBCL早期复发预测提供参考。 Objective To predict whether the newly diagnosed diffuse large B-cell lymphoma patients in a third-class hospital in Shanxi Province from 2011 to 2017 can achieve two-year event-free survival,that is,the prediction of early recurrence of DLBLC patients.Methods According to the event-free survival time,the patients were divided into early recurrence and non-early recurrence,and the classification model was constructed.Firstly,the data is normalized,and then the feature is selected by LASSO.Because of the data imbalance,four methods are used to balance the data:SMOTE(synthetic minority over-sampling technique),Borderline-1SMOTE,Borderline-2 SMOTE and ADASYN(adaptive synthetic sampling),respectively.Then a Multi-Kernel model based on support vector machine is constructed as the final classifier.And compared with AdaBoost,Random Forest and Single-Kernel support vector machine with Gaussian kernel and polynomial kernel as kernel,and finally realized the prediction of early recurrence of newly diagnosed cases.Results The Multi-Kernel model with LASSO plus Borderline-1 SMOTE(accuracy=0.87,precision=0.87,recall=0.87,f1=0.87,AUC=0.87)achieved the best classification performance.The classification performance of the two integrated models Random Forest(accuracy=0.84,precision=0.85,recall=0.87,f1=0.79,AUC=0.83)of SMOTE and Random Forest(accuracy=0.84,precision=0.85,recall=0.87,f1=0.79,AUC=0.83)of Borderline-2 SMOTE are also better,but they are lower than the Multi-Kernel support vector machine model.The performance of two kinds of Single-Kernel support vector machines is poor.Conclusion Among all the models in this paper,the Multi-Kernel support vector machine with LASSO and Borderline-1 SMOTE has the best performance,which can provide reference for the prediction of early recurrence of DLBCL.
作者 邢蒙 周洁 余红梅 张岩波 阳桢寰 赵艳琳 李雪玲 李琼 赵志强 罗艳虹 Xing Meng;Zhou Jie;Yu Hongmei(Department of Health Statistic,School of Public Health,Shanxi Medical University 030001,Taiyuan)
出处 《中国卫生统计》 CSCD 北大核心 2022年第4期518-521,528,共5页 Chinese Journal of Health Statistics
基金 山西省科技厅应用基础研究计划面上项目(202103021224245) 国家自然科学基金青年科学基金(81502897) 山西医科大学博士启动基金(BS2017029) 国家自然科学基金面上项目(81973154)。
关键词 弥漫大B细胞淋巴瘤 早期复发 多核学习 不平衡数据 Diffuse large B lymphoma Early recurrence Multiple kernel learning Imbalance data
  • 相关文献

参考文献7

二级参考文献40

  • 1刘向东,骆斌,陈兆乾.支持向量机最优模型选择的研究[J].计算机研究与发展,2005,42(4):576-581. 被引量:49
  • 2Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139. 被引量:1
  • 3Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41. 被引量:1
  • 4Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006. 被引量:1
  • 5Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205. 被引量:1
  • 6Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045. 被引量:1
  • 7Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266. 被引量:1
  • 8Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033. 被引量:1
  • 9Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127. 被引量:1
  • 10Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69. 被引量:1

共引文献277

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部